Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Total Current Liabilities (2020 - 2025)

Historic Total Current Liabilities for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $279.5 million.

  • Apellis Pharmaceuticals' Total Current Liabilities rose 4615.03% to $279.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $279.5 million, marking a year-over-year increase of 4615.03%. This contributed to the annual value of $185.5 million for FY2024, which is 2507.5% down from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Total Current Liabilities stood at $279.5 million for Q3 2025, which was up 4615.03% from $200.7 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' 5-year Total Current Liabilities high stood at $279.5 million for Q3 2025, and its period low was $83.7 million during Q1 2021.
  • Over the past 5 years, Apellis Pharmaceuticals' median Total Current Liabilities value was $169.2 million (recorded in 2024), while the average stood at $166.8 million.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Total Current Liabilities skyrocketed by 17209.35% in 2021, and later plummeted by 2507.5% in 2024.
  • Over the past 5 years, Apellis Pharmaceuticals' Total Current Liabilities (Quarter) stood at $131.8 million in 2021, then increased by 27.12% to $167.6 million in 2022, then soared by 47.72% to $247.6 million in 2023, then dropped by 25.08% to $185.5 million in 2024, then soared by 50.68% to $279.5 million in 2025.
  • Its last three reported values are $279.5 million in Q3 2025, $200.7 million for Q2 2025, and $178.4 million during Q1 2025.